
Ovarian immature teratoma (IT) is a rare neoplasm comprising ∼3% of ovarian cancers, occurring primarily in young females. In this case report a 17-year-old female was diagnosed with immature teratoma. The patient presented mass and dull aching pain in abdomen for duration of 6 months. On examination 20x15cm intraabdominal mass was noted which occupied whole of abdomen more on the right side, hard in consistency, mobile and lower border felt per vaginally in right fornix. CECT abdomen was done which showed a well-defined solid to cystic abdominopelvic mass measuring 20.3x 6.2x 15.8 cm probably arising from the right ovary. CECT chest was normal. Tumour markers S. Beta-hCG was 2 mIU/mL, S. LDH was 357 IU/mL, S. AFP was 1065 IU/ mL and S.CA-125 was 55.26 IU/mL. After multidisciplinary tumuor board discussion patient was planned for staging ovarian laparotomy (fertility preserving surgery). Intraoperatively ascites was present, mass was found to be arising from the right ovary measuring about 20 x15 cm free from all intraabdominal organs. Right fallopian tube and uterus was normal. Left ovary and fallopian tube was normal. Right pelvic, paracaval and precaval lymph nodes was enlarged. Liver, bilateral diaphragm and rest of the peritoneal cavity was normal. Patient underwent right ovarian mass excision with right salpingectomy, bilateral pelvic lymph node dissection, retroperitoneal lymph node dissection and supracolic omentectomy. On histopathological examination right ovary was reported as immature teratoma, grade 2 (high grade). Right fallopian tube, bilateral pelvic lymph nodes, supracolic omentum, retroperitoneal lymph nodes and ascitic fluid were free of tumour. On immunohistochemistry (IHC), right ovary tissue was positive for S-100 (highlighting immature neuroblast component) and SALL4 (germ cell tumour marker). From above findings, diagnosis of immature teratoma of right ovary was made FIGO stage IA (TNM stage pT1a pN0). Patient was advised adjuvant chemotherapy with Bleomycin, Etoposide and Cisplatin (BEP).
Myopericytoma is a rare benign neoplasm belonging to spectrum of perivascular myoid tumors that shows hemangiopericytoma like growth pattern. It was first described as distinct entity by Stout and Murray in 1942.It is characterized by proliferation of myoid appearing cells arranged concentrically around vascular channels.These tumors are encountered more commonly in distal extremities, particularly in lower extremities as slow growing painless tumors in superficial or deep soft tissues.[1] However they can also occur in other locations including proximal extremities, head, lungs,muscle and bone.[2]
Background : Schwannoma is a benign tumor that arises from the nerve sheath that consists of neoplastic Schwann cells. Case Scenarios: A case of 59 years-old women presented to neurosurgery unit with complained of lower back and right lower limb radiating pain which getting worse with activity. She complained about back pain since the last 5 months which was gradually increased. MRI showed a well-defined, longitudinally ovoid, sausage-shaped, solid-cystic, intradural extra-medullary, well-defined, encapsulated mass lesion measuring 2.8x1.3x1.0 cm. extending from lower border of L3 to upper border of L4 vertebral level. The imaging suggestive of mass-schwannoma lesion. On histopathology reported as primary intradural extramedullary spinal Schwannoma. On immunohistochemistry tumor cells revealed strong, diffuse S100, SOX10 positivity and negative for EMA. Ki-67 proliferation index (MIB 1) was 2-3%. Conclusion : Primary intradural extramedullary spinal schwannomas are uncommon tumor. The diagnosis of lumbar schwannomas is generally established through a combination of clinical history, physical examination, radiological imaging, and histopathological analysis. The management is generally with surgical excision which showed complete cure with a very low risk of recurrence. This article is review on clinical, pathological, radio imaging, histopathological features and management updates on spinal schwannomas. Keywords - Spinal tumor, Lumbar Schwannomas, Intradural extramedullary spinal tumor, SOX10 immunohistochemistry.
Anal canal squamous cell carcinoma (SCC) is an uncommon malignancy treated primarily with definitive chemoradiotherapy (CCRT). However, treatment responses and long-term outcomes remain heterogeneous. We retrospectively analysed six patients with non-metastatic anal canal SCC treated with definitive CCRT between 2019 and 2024 at a tertiary oncology centre. Clinical presentation, treatment techniques, toxicities, response patterns, salvage interventions, and survival outcomes were evaluated. Stages ranged from IIA to IIIC. Radiotherapy techniques included 3DCRT, IMRT, and VMAT with concurrent mitomycin-based chemotherapy. Four patients achieved durable disease control, including one after salvage pelvic exenteration. Two patients developed persistent or recurrent disease and subsequently died. Acute toxicities were manageable, with only one Grade 3 dermatitis event . Anal canal SCC demonstrates variable clinical behaviour despite standardized CCRT. Careful response assessment, individualized surveillance, and timely salvage treatment remain crucial for optimizing outcomes .